RLYB Stock Performance, Insider Transaction and News

RLYB - Rallybio Corporation

Market Cap	220.07M	P/E	-	EPS this Y	16.80%	Ern Qtrly Grth	-
Income	-73.88M	Forward P/E	-2.75	EPS next Y	10.50%	50D Avg Chg	-12.00%
Sales	299k	PEG	-	EPS past 5Y	-	200D Avg Chg	-9.00%
Dividend	N/A	Price/Book	1.42	EPS next 5Y	-	52W High Chg	-63.00%
Recommedations	2.20	Quick Ratio	7.29	Shares Outstanding	41.49M	52W Low Chg	40.00%
Insider Own	4.06%	ROA	-38.54%	Shares Float	19.61M	Beta	-1.71
Inst Own	77.30%	ROE	-67.39%	Shares Shorted/Prior	579.07K/623.33K	Price	5.83
Gross Margin	250.50%	Profit Margin	-	Avg. Volume	100,858	Target Price	10.50
Oper. Margin	-5,697.32%	Earnings Date	-	Volume	33,940	Change	-2.67%

Healthcare | Biotechnology | United States

About Rallybio Corporation

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Rallybio Corporation News

07:01 AM	Rallybio commences Phase II trial of RLYB212 for FNAIT in pregnant women
11/21/24	Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
11/13/24	3 US Penny Stocks With Market Caps Over $40M To Consider
11/07/24	Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/05/24	Two former Alexion leaders fight through a tough market to maintain a rare disease biotech
10/29/24	Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT
09/30/24	Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting
09/23/24	Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
09/10/24	Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit
09/09/24	Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree
08/29/24	Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
08/27/24	Rallybio to Present at Upcoming Investor Conferences
08/14/24	Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock?
08/10/24	Is Rallybio (NASDAQ:RLYB) In A Good Position To Invest In Growth?
08/08/24	Rallybio Reports Second Quarter 2024 Financial Results and Provides Business Updates
07/09/24	Rallybio to Present at the 2024 Jones Healthcare Seaside Summit
06/17/24	Rallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations
05/31/24	3 Sorry Biotech Stocks to Sell in May While You Still Can
05/10/24	3 Biotech Stocks to Sell in May Before They Crash & Burn
05/09/24	Rallybio Reports First Quarter 2024 Financial Results and Provides Business Updates

RLYB Chatroom

Dani_G_German Posted - 3 days ago

$ICCM $RLYB

Dani_G_German Posted - 3 days ago

$RLYB https://www.sec.gov/Archives/edgar/data/1739410/000031506624002857/filing.txt

Mister___B Posted - 1 week ago

$RLYB cooking again

VincM Posted - 1 week ago

$RLYB

kylehurlbut Posted - 1 week ago

$RLYB RS comming

kylehurlbut Posted - 1 week ago

$RLYB 8.50 my A$$

VincM Posted - 2 weeks ago

$RLYB soon as well 🚀

VincM Posted - 2 weeks ago

$RLYB don’t forget this one 🚀

VincM Posted - 2 weeks ago

$RLYB 🚀 buy dips

justiceforb_85 Posted - 10/29/24

$RLYB promising phase 1 proof-of-concept for RLYB212. About to start phase 2 for patients at risk for FNAIT. Look forward to this potentially going up in value.

BagholderDisinfectant Posted - 4 weeks ago

$RLYB LOL, looks like the price ain’t rallying, am I right?

VrtcIl Posted - 1 month ago

Exercise patience and wait for pullbacks in $RLYB as potential opportunities for entering positions at safer and more advantageous points. Monitoring the chart during these retracements can provide a more strategic and risk-averse entry. Price: 1.04 Float: 16.9M Short Float: 2.9 % 💰 Dollar Volume: 0.3K ℹ️ USA | Biotechnology

VolatileGems Posted - 1 month ago

$RLYB Watching closely it's been sitting in this range far too long, I think It Could go crazy if news comes for it

Mister___B Posted - 1 month ago

$RLYB volume picking up a little? Bullish

NeoTrinityTrading Posted - 1 month ago

$RLYB opened a position here based on price point is attractive, catalyst coming, more than one year of cash. Currently under low volume. Always complete your own DD.

justiceforb_85 Posted - 1 month ago

$RLYB $XBI promising data on RLYB212. Phase 2 doesn't start until later this year. Perhaps now is a good entry point? Stock is at a low...

The_Claw Posted - 09/24/24

$RLYB

PhishTourFunds Posted - 2 months ago

$RLYB

Stock_Titan Posted - 2 months ago

$RLYB Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree https://www.stocktitan.net/news/RLYB/fierce-names-rallybio-to-the-2024-fierce-50-list-as-an-innovation-d54vqt2b4t2a.html

The_Claw Posted - 2 months ago

$RLYB This one is hardly a thrill a minute at this point, but it’s nice to see the volume picking up a bit.

DonCorleone77 Posted - 08/29/24

$RLYB Rallybio announces data from Phase 1 PoC sudy of RLYB212 Rallybio announced that data from the Phase 1 proof-of-concept study of RLYB212, a novel monoclonal anti-HPA-1a antibody in development for the prevention of maternal alloimmunization and fetal and neonatal alloimmune thrombocytopenia FNAIT , were published in Thrombosis and Haemostasis. Top-line results from this study were previously presented at the 31st Congress of the International Society on Thrombosis and Haemostasis ISTH in 2023.... Rallybio is on track to initiate a Phase 2 dose confirmation trial in pregnant women at higher risk for HPA-1a alloimmunization and FNAIT in the fourth quarter of 2024. The Company also continues to screen pregnant women in its ongoing FNAIT natural history study, which is designed to provide a contemporary dataset for HPA-1a alloimmunization frequency in a racially and ethnically diverse population that can serve as a control arm for a planned Phase 3 trial.

Stock_Titan Posted - 08/29/24

$RLYB Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis https://www.stocktitan.net/news/RLYB/rallybio-announces-publication-of-rlyb212-phase-1-proof-of-concept-yfg7bgu73kl8.html

The_Claw Posted - 08/27/24

$RLYB

LewisDaKat Posted - 08/27/24

$RLYB News Article Rallybio to Present at Upcoming Investor Conferences https://marketwirenews.com/news-releases/rallybio-to-present-at-upcoming-investor-conferences-6429284983961828.html $RLYB

Mister___B Posted - 08/27/24

$RLYB moving, needs volume

VelocityViper Posted - 08/23/24

$RLYB Peace of shit ticker

The_Claw Posted - 2 months ago

$RLYB Sometimes you strike when things are hot and sometimes you exercise patience. Be one of the cool kids and get in this early.

VelocityViper Posted - 3 months ago

$RLYB Hope this gets news soon all times low rn lol

PhishTourFunds Posted - 3 months ago

$RLYB Bios poppin

makedatbread88 Posted - 3 months ago

Bios I am watching $RLYB $ATHA $VERU $ATOS $LPTX

Analyst Ratings

HC Wainwright & Co.	Buy	Oct 1, 24
HC Wainwright & Co.	Buy	Sep 3, 24
Evercore ISI Group	Outperform	Aug 26, 24
HC Wainwright & Co.	Buy	Aug 12, 24
JP Morgan	Neutral	May 15, 24
HC Wainwright & Co.	Buy	May 10, 24
JMP Securities	Market Outperform	Apr 19, 24
JMP Securities	Market Outperform	Apr 18, 24
Wedbush	Outperform	Apr 11, 24

Insider Trades	Relationship	Date	Transactions	Cost($)	#Shares	Value($)	#Share Own	SEC Form 4
PARMAR KUSH	Director Director	Mar 07	Sell	8.20	100,000	820,000	2,378,969	03/09/23
5AM Partners V, LLC	10% Owner 10% Owner	Mar 07	Sell	8.20	100,000	820,000	2,378,969	03/09/23
PARMAR KUSH	Director Director	Jun 03	Sell	12.5	150,000	1,875,000	1,251,755	06/07/22
5AM Opportunities I, L.P.	10% Owner 10% Owner	Jun 03	Sell	12.5	150,000	1,875,000	2,478,969	06/07/22
PARMAR KUSH	Director Director	May 23	Sell	13	100,000	1,300,000	1,302,084	05/25/22
5AM Opportunities I, L.P.	10% Owner 10% Owner	May 23	Sell	13	100,000	1,300,000	2,578,640	05/25/22
Fryer Jeffrey M	See Remarks See Remarks	Mar 21	Buy	8.04	3,000	24,120	47,048	03/23/22
5AM Opportunities I, L.P.	10% Owner 10% Owner	Feb 08	Sell	13.05	210,000	2,740,500	2,645,087	02/10/22
PARMAR KUSH	Director Director	Feb 08	Sell	13.05	210,000	2,740,500	1,335,637	02/10/22
Fryer Jeffrey M	See Remarks See Remarks	Jan 19	Buy	8.70	1,400	12,180	44,048	01/21/22
Uden Stephen	See Remarks See Remarks	Jul 28	Buy	9.74	10,000	97,400	719,127	01/14/22
MACKAY MARTIN	Chief Executive Offi.. Chief Executive Officer	Jul 28	Buy	10.38	10,000	103,800	282,609	01/12/22
Fryer Jeffrey M	See Remarks See Remarks	Jul 28	Buy	9.21	10,000	92,100	42,648	01/11/22